Publications by authors named "Emily Karanges"

Claim this Profile
S
Substance use patterns among youth seeking help for mental illness: A latent class analysis.
Emily A Karanges, Alexandre A Guerin, Sasha Malignaggi, Rosemary Purcell, Patrick McGorry

Addict Behav· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Australian Clinical Trial Authors' Declarations of Industry Ties.
Lorelie Flood, Barbara Mintzes, Kellia Chiu, Zhaoli Dai, Emily A Karanges

J Gen Intern Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in transdermal fentanyl utilisation and fatal fentanyl overdose across Australia (2003-2015).
Shafkat Rahman, Alex Trussell, Sallie-Anne Pearson, Nicholas A Buckley, Emily A Karanges

Drug Alcohol Rev· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of educational events for physicians and nurses in Australia sponsored by opioid manufacturers.
Quinn Grundy, Sasha Mazzarello, Sarah Brennenstuhl, Emily A Karanges

PLoS One· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study.
Emily Aspasia Karanges, Conrad Nangla, Lisa Parker, Alice Fabbri, Cynthia Farquhar

BMJ Open· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"There are ways … drug companies will get into DTC decisions": How Australian drug and therapeutics committees address pharmaceutical industry influence.
Lisa Parker, Alexandra Bennett, Barbara Mintzes, Quinn Grundy, Alice Fabbri, Emily A Karanges

Br J Clin Pharmacol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The changing face of Australian data reforms: impact on pharmacoepidemiology research.
Juliana de Oliveira Costa, Claudia Bruno, Andrea L Schaffer, Smriti Raichand, Emily A Karanges

Int J Popul Data Sci· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Policies affecting the supply and access of opioid analgesics: a scoping review protocol.
Kellia Chiu, Sally McDonald, Tess Legg, Emily A Karanges, Lisa Bero

JBI Evid Synth· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes.
Emily A Karanges, Natasha Ting, Lisa Parker, Alice Fabbri, Lisa Bero

Aust J Gen Pract· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the Nature and Extent of Pharmaceutical Industry Payments to Nonphysician Clinicians.
Emily A Karanges, Quinn Grundy, Lisa Bero

JAMA Intern Med· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study.
Behrad Behdarvand, Emily A Karanges, Lisa Bero

BMJ Open· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.
Lisa Parker, Emily A Karanges, Lisa Bero

BMJ Open· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in self-poisoning and psychotropic drug use in people aged 5-19 years: a population-based retrospective cohort study in Australia.
Rose Cairns, Emily A Karanges, Anselm Wong, Jared A Brown, Jeff Robinson

BMJ Open· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study.
Andrea L Schaffer, Emily A Karanges, Nicholas A Buckley, Andrew Wilson, Louisa Degenhardt

Pharmacoepidemiol Drug Saf· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey.
Emily A Karanges, Anastasia Suraev, Natalie Elias, Ramesh Manocha, Iain S McGregor

BMJ Open· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescription Opioid Access Patterns and Factors Associated with Increasing Number of Prescribers, Pharmacies, and Dispensings: An Observational Study Using Pharmaceutical Claims.
Bianca Blanch, Louisa Degenhardt, Nicholas A Buckley, Natasa Gisev, Timothy Dobbins, Emily A Karanges

Pain Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?
Natasa Gisev, Sallie-Anne Pearson, Emily A Karanges, Briony Larance, Nicholas A Buckley

Pharmacoepidemiol Drug Saf· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in opioid utilisation in Australia, 2006-2015: Insights from multiple metrics.
Emily A Karanges, Nicholas A Buckley, Jonathan Brett, Bianca Blanch, Melisa Litchfield

Pharmacoepidemiol Drug Saf· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study.
Jonathan Brett, Benjamin Daniels, Emily A Karanges, Nicholas A Buckley, Carl Schneider

Br J Clin Pharmacol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure.
Jonathan Brett, Emily A Karanges, Benjamin Daniels, Nicholas A Buckley, Carl Schneider

Aust N Z J Psychiatry· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims.
Emily A Karanges, Bianca Blanch, Nicholas A Buckley, Sallie-Anne Pearson

Br J Clin Pharmacol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contrasting regional Fos expression in adolescent and young adult rats following acute administration of the antidepressant paroxetine.
Emily A Karanges, Linnet Ramos, Bruno Dampney, Anastasia S Suraev, Kong M Li

Brain Res Bull· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers.
Leigh Mellish, Emily A Karanges, Melisa J Litchfield, Andrea L Schaffer, Bianca Blanch

BMC Res Notes· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009-2012: focus on children, adolescents and prescriber specialty.
Emily A Karanges, Chris P Stephenson, Iain S McGregor

Aust N Z J Psychiatry· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis